LMAN1L

Summary

LMAN1L (lectin, mannose binding 1 like, HGNC:6632) is a protein-coding gene on chromosome 15q24.1, encoding Protein ERGIC-53-like (Q9HAT1).

This gene encodes a mannose-binding type 1 transmembrane protein that contains an N-terminal lectin-like carbohydrate recognition domain. The encoded protein is similar in structure to lectins found in leguminous plants. This lectin is thought to transport newly synthesized glycoproteins from the endoplasmic reticulum (ER) to the ER-Golgi intermediate compartment.

Source: NCBI Gene 79748 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 88 total
• MANE Select transcript: NM_021819

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6632
Approved symbol	LMAN1L
Name	lectin, mannose binding 1 like
Location	15q24.1
Locus type	gene with protein product
Status	Approved
Aliases	ERGL, ERGIC-53L
Ensembl gene	ENSG00000140506
Ensembl biotype	protein_coding
OMIM	609548
Entrez	79748

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 17 protein_coding, 6 retained_intron

ENST00000309664, ENST00000379709, ENST00000456603, ENST00000470711, ENST00000562810, ENST00000565585, ENST00000566046, ENST00000567848, ENST00000568467, ENST00000570147, ENST00000856995, ENST00000947244, ENST00000947245, ENST00000947246, ENST00000947247, ENST00000947248, ENST00000947250, ENST00000947251, ENST00000947252, ENST00000947253, ENST00000947254, ENST00000947255, ENST00000947256

RefSeq mRNA: 1 — MANE Select: NM_021819 NM_021819

CCDS: CCDS10270

Canonical transcript exons

ENST00000309664 — 14 exons

Exon	Start	End
ENSE00001331983	74825476	74825754
ENSE00001607595	74820044	74820099
ENSE00001795670	74819152	74819272
ENSE00001813064	74812835	74813029
ENSE00003458700	74821075	74821226
ENSE00003476718	74820635	74820767
ENSE00003485447	74816157	74816311
ENSE00003501312	74821829	74821900
ENSE00003542265	74824351	74824478
ENSE00003565784	74822642	74822709
ENSE00003586087	74823559	74823682
ENSE00003592165	74816427	74816534
ENSE00003629521	74818718	74818817
ENSE00003661151	74816632	74816690

Expression profiles

Bgee: expression breadth ubiquitous, 108 present calls, max score 95.26.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2773 / max 91.1690, expressed in 30 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
147732	0.1277	13
147735	0.0873	10
147731	0.0623	15

Top tissues by expression

122 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right atrium auricular region	UBERON:0006631	95.26	gold quality
apex of heart	UBERON:0002098	93.42	gold quality
right hemisphere of cerebellum	UBERON:0014890	91.23	gold quality
spleen	UBERON:0002106	90.97	gold quality
cerebellar hemisphere	UBERON:0002245	90.64	gold quality
cerebellar cortex	UBERON:0002129	90.56	gold quality
cerebellum	UBERON:0002037	90.52	gold quality
prostate gland	UBERON:0002367	89.18	gold quality
saliva-secreting gland	UBERON:0001044	76.87	gold quality
heart	UBERON:0000948	75.83	gold quality
minor salivary gland	UBERON:0001830	75.63	gold quality
heart left ventricle	UBERON:0002084	75.21	gold quality
right adrenal gland cortex	UBERON:0035827	69.64	gold quality
right adrenal gland	UBERON:0001233	68.79	gold quality
tonsil	UBERON:0002372	67.17	gold quality
left adrenal gland cortex	UBERON:0035825	66.91	gold quality
left adrenal gland	UBERON:0001234	66.40	gold quality
lower esophagus mucosa	UBERON:0035834	65.11	gold quality
adrenal gland	UBERON:0002369	64.81	gold quality
fundus of stomach	UBERON:0001160	59.80	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	59.14	gold quality
right testis	UBERON:0004534	54.59	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	54.30	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	52.68	gold quality
granulocyte	CL:0000094	52.48	gold quality
pituitary gland	UBERON:0000007	52.44	gold quality
testis	UBERON:0000473	52.44	gold quality
left testis	UBERON:0004533	52.28	gold quality
stromal cell of endometrium	CL:0002255	51.83	silver quality
esophagus mucosa	UBERON:0002469	51.67	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.15

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

4 targeting LMAN1L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-302B-5P	99.50	69.49	1857
HSA-MIR-302D-5P	99.50	69.34	1863
HSA-MIR-1233-5P	98.19	66.71	1201
HSA-MIR-3943	95.87	64.57	523

Literature-anchored findings (GeneRIF, showing 3)

• ERGIC-53 provides a platform that receives micro(2)L(2) subunits from the BiP-dependent checkpoint, assisting polymerization. In this process, ERp44 couples thiol-dependent assembly and quality control. (PMID:17805346)
• Binding of ERGIC-53 to sugar is enhanced by its interaction with MCFD2, and defects in this interaction in factor V and VIII deeficient patients may be the cause for reduced secretion of factors V and VIII. (PMID:18056485)
• The results reveal ERGIC-53 to be an intracellular transport receptor of alpha1-AT and provide direct evidence for active receptor-mediated ER export of a soluble secretory protein in higher eukaryotes (PMID:18283111)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
mus_musculus	Lman1l	ENSMUSG00000056271
rattus_norvegicus	Lman1l	ENSRNOG00000019355
drosophila_melanogaster	ergic53	FBGN0035909
drosophila_melanogaster	CG5510	FBGN0039160
caenorhabditis_elegans	ile-1	WBGENE00002070
caenorhabditis_elegans		WBGENE00002071

Paralogs (3): LMAN1 (ENSG00000074695), LMAN2L (ENSG00000114988), LMAN2 (ENSG00000169223)

Protein

Protein identifiers

Protein ERGIC-53-like — Q9HAT1 (reviewed: Q9HAT1)

Alternative names: ERGIC53-like protein, Lectin mannose-binding 1-like

All UniProt accessions (3): Q9HAT1, H3BN74, H3BSC9

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Endoplasmic reticulum-Golgi intermediate compartment membrane.

Tissue specificity. Highly expressed in normal and neoplastic prostate. Also expressed in cardiac atrium, salivary gland, spleen and selective cells in the CNS.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9HAT1-1	1	yes
Q9HAT1-2	2
Q9HAT1-3	3

RefSeq proteins (1): NP_068591* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005052	Lectin_leg	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR051136	Intracellular_Lectin-GPT	Family

Pfam: PF03388

UniProt features (13 total): sequence variant 2, sequence conflict 2, topological domain 2, signal peptide 1, chain 1, transmembrane region 1, domain 1, glycosylation site 1, disulfide bond 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HAT1-F1	68.96	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 176–215

Glycosylation sites (1): 75

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-204005	COPII-mediated vesicle transport
R-HSA-5694530	Cargo concentration in the ER
R-HSA-199977	ER to Golgi Anterograde Transport
R-HSA-199991	Membrane Trafficking
R-HSA-392499	Metabolism of proteins
R-HSA-446203	Asparagine N-linked glycosylation
R-HSA-5653656	Vesicle-mediated transport
R-HSA-597592	Post-translational protein modification
R-HSA-948021	Transport to the Golgi and subsequent modification

MSigDB gene sets: 0 (showing top):

GO Biological Process (1): endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888)

GO Molecular Function (2): D-mannose binding (GO:0005537), carbohydrate binding (GO:0030246)

GO Cellular Component (8): Golgi membrane (GO:0000139), endoplasmic reticulum membrane (GO:0005789), endoplasmic reticulum-Golgi intermediate compartment (GO:0005793), COPII-coated ER to Golgi transport vesicle (GO:0030134), extracellular matrix (GO:0031012), endoplasmic reticulum-Golgi intermediate compartment membrane (GO:0033116), endomembrane system (GO:0012505), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
ER to Golgi Anterograde Transport	2
Membrane Trafficking	1
Transport to the Golgi and subsequent modification	1
Vesicle-mediated transport	1
Post-translational protein modification	1
Metabolism of proteins	1
Asparagine N-linked glycosylation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
bounding membrane of organelle	2
cellular anatomical structure	2
intercellular transport	1
intracellular transport	1
Golgi vesicle transport	1
monosaccharide binding	1
binding	1
Golgi apparatus	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
intracellular membrane-bounded organelle	1
coated vesicle	1
external encapsulating structure	1
endoplasmic reticulum-Golgi intermediate compartment	1
vacuole	1
plasma membrane	1

Protein interactions and networks

STRING

596 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LMAN1L	MCFD2	Q8NI22	575
LMAN1L	FAM219B	Q5XKK7	447
LMAN1L	ULK3	Q6PHR2	444
LMAN1L	MEGF11	A6BM72	443
LMAN1L	SCAMP2	O15127	435
LMAN1L	CCDC33	Q8N5R6	420
LMAN1L	CIMAP1D	Q3SX64	405
LMAN1L	PRMT2IP	Q6ZRI6	370
LMAN1L	SCAMP5	Q8TAC9	370
LMAN1L	LRRC38	Q5VT99	350
LMAN1L	SURF4	O15260	346
LMAN1L	EML6	Q6ZMW3	346
LMAN1L	CRACDL	Q6NV74	339
LMAN1L	GOLGA6A	Q9NYA3	335
LMAN1L	ZNF549	Q6P9A3	328

IntAct

3 interactions, top by confidence:

A	B	Type	Score
LMAN1L	LRRK1	psi-mi:“MI:0407”(direct interaction)	0.440
LMAN1L	LMAN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): LMAN1L (Affinity Capture-MS), LMAN1L (Negative Genetic), SPCS1 (Affinity Capture-MS), MAN2A2 (Affinity Capture-MS), SPCS2 (Affinity Capture-MS), TMEM38B (Affinity Capture-MS), SEC11C (Affinity Capture-MS), FKBP14 (Affinity Capture-MS), LMAN1 (Affinity Capture-MS)

ESM2 similar proteins: A0A061IR73, A2ARS0, A6NE52, A6QPE7, A8MYJ7, A8VU90, C9JTQ0, E1BD59, E5RJM6, O08672, P54777, Q08353, Q0P5G1, Q0V8J4, Q13470, Q13608, Q15653, Q28616, Q2TB02, Q3SWY4, Q3UYR4, Q53GL7, Q58EX7, Q5IJ48, Q5JR98, Q60778, Q62893, Q6EMK4, Q6F5E8, Q6MG64, Q6P7C4, Q6UX07, Q6ZMH5, Q6ZVH7, Q6ZVZ8, Q7RTR2, Q8CDY7, Q8CIE4, Q8K592, Q8NI38

Diamond homologs: P49256, P49257, P59481, Q12907, Q2HJD1, Q5FB95, Q5RCF0, Q62902, Q8VCD3, Q9D0F3, Q9DBH5, Q9H0V9, Q9HAT1, Q9TU32, O94401

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

88 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	75
Likely benign	10
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2291 predictions. Top by Δscore:

Variant	Effect	Δscore
15:74816255:G:GT	donor_gain	1.0000
15:74816255:G:T	donor_gain	1.0000
15:74816151:CCACA:C	acceptor_loss	0.9900
15:74816152:CACA:C	acceptor_loss	0.9900
15:74816153:ACAG:A	acceptor_loss	0.9900
15:74816154:CAGAC:C	acceptor_loss	0.9900
15:74816155:A:AG	acceptor_gain	0.9900
15:74816155:AGA:A	acceptor_loss	0.9900
15:74816156:G:GG	acceptor_gain	0.9900
15:74816156:GAC:G	acceptor_gain	0.9900
15:74816631:GGACA:G	acceptor_gain	0.9900
15:74816687:CTGGG:C	donor_loss	0.9900
15:74816689:GG:G	donor_gain	0.9900
15:74816690:GG:G	donor_gain	0.9900
15:74816690:GGTAA:G	donor_loss	0.9900
15:74816691:G:GA	donor_loss	0.9900
15:74816691:G:GG	donor_gain	0.9900
15:74816692:T:A	donor_loss	0.9900
15:74820140:G:T	donor_gain	0.9900
15:74823691:A:T	donor_gain	0.9900
15:74816156:GA:G	acceptor_gain	0.9800
15:74816626:CTGCA:C	acceptor_loss	0.9800
15:74816629:CA:C	acceptor_loss	0.9800
15:74816631:G:GA	acceptor_loss	0.9800
15:74817681:G:GT	donor_gain	0.9800
15:74820125:G:GT	donor_gain	0.9800
15:74820126:A:T	donor_gain	0.9800
15:74820139:G:GT	donor_gain	0.9800
15:74820763:AGAAG:A	donor_loss	0.9800
15:74820764:GAAGG:G	donor_loss	0.9800

AlphaMissense

3388 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:74812966:A:C	S38R	0.940
15:74812968:C:A	S38R	0.940
15:74812968:C:G	S38R	0.940
15:74812969:T:C	F39L	0.928
15:74812971:C:A	F39L	0.928
15:74812971:C:G	F39L	0.928
15:74816225:A:C	S82R	0.917
15:74816227:C:A	S82R	0.917
15:74816227:C:G	S82R	0.917
15:74813011:T:C	F53L	0.913
15:74813013:C:A	F53L	0.913
15:74813013:C:G	F53L	0.913
15:74816254:G:C	W91C	0.910
15:74816254:G:T	W91C	0.910
15:74820073:T:C	F250L	0.909
15:74820075:C:A	F250L	0.909
15:74820075:C:G	F250L	0.909
15:74818758:T:C	F180L	0.906
15:74818760:C:A	F180L	0.906
15:74818760:C:G	F180L	0.906
15:74812951:T:C	F33L	0.900
15:74812953:T:A	F33L	0.900
15:74812953:T:G	F33L	0.900
15:74820064:T:C	F247L	0.900
15:74820066:C:A	F247L	0.900
15:74820066:C:G	F247L	0.900
15:74816252:T:A	W91R	0.889
15:74816252:T:C	W91R	0.889
15:74812974:A:C	K40N	0.876
15:74812974:A:T	K40N	0.876

dbSNP variants (sampled 300 via entrez): RS1000012172 (15:74821966 C>A,T), RS1000343289 (15:74817591 G>C), RS1000418064 (15:74824089 CTCTCT>C,CTCTCTTCTCT), RS1000868907 (15:74823850 T>C), RS1001107895 (15:74811692 G>A), RS1001470599 (15:74822526 C>T), RS1002419572 (15:74815776 C>T), RS1002823907 (15:74813747 G>C), RS1002903086 (15:74815489 C>T), RS1003066805 (15:74826079 G>T), RS1003271473 (15:74814199 T>C), RS1003361937 (15:74825680 C>T), RS1003600630 (15:74818967 C>T), RS1003608858 (15:74813810 G>A), RS1004061620 (15:74816476 G>A,T)

Disease associations

OMIM: gene MIM:609548 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST000394_3	Diastolic blood pressure	1.000000e-23
GCST001032_3	Caffeine consumption	6.000000e-07
GCST001032_7	Caffeine consumption	5.000000e-14
GCST006167_67	Mean arterial pressure x alcohol consumption interaction (2df test)	4.000000e-15
GCST006170_10	Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)	4.000000e-14
GCST006172_31	Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)	3.000000e-15
GCST006231_65	Mean arterial pressure	2.000000e-15
GCST006434_66	Systolic blood pressure x alcohol consumption interaction (2df test)	8.000000e-28
GCST007934_2	Medication use (anti-inflammatory and antirheumatic products, non-steroids)	4.000000e-08
GCST010204_26	Low density lipoprotein cholesterol levels	4.000000e-08
GCST010243_254	Apolipoprotein B levels	3.000000e-09
GCST010245_65	LDL cholesterol levels	1.000000e-11
GCST90002400_162	Plateletcrit	6.000000e-14
GCST90002401_99	Platelet distribution width	6.000000e-24

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0004330	coffee consumption
EFO:0004329	alcohol drinking
EFO:0006340	mean arterial pressure
EFO:0006335	systolic blood pressure
EFO:0009935	Non-steroidal anti-inflammatory and antirheumatic product use measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004615	apolipoprotein B measurement
EFO:0007985	platelet crit
EFO:0007984	platelet component distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
acyline	decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	affects response to substance	1
Fulvestrant	increases methylation	1
Benzo(a)pyrene	increases methylation	1
Carmustine	affects response to substance	1
Estradiol	increases expression	1
Lead	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Testosterone	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer